Go Pro

Zoetis (ZTS) Stock Forecast & Price Target

Zoetis logo
$75.28 -1.01 (-1.33%)
As of 11:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Zoetis - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
2
Hold
9
Buy
8

Based on 19 Wall Street analysts who have issued ratings for Zoetis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 2 have given a sell rating, 9 have given a hold rating, and 8 have given a buy rating for ZTS.

Consensus Price Target

$107.43
42.71% Upside
According to the 19 analysts' twelve-month price targets for Zoetis, the average price target is $107.43. The highest price target for ZTS is $190.00, while the lowest price target for ZTS is $80.00. The average price target represents a forecasted upside of 42.71% from the current price of $75.28.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ZTS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zoetis and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZTS Analyst Ratings Over Time

TypeCurrent Forecast
9/4/25 to 9/4/26
1 Month Ago
8/5/25 to 8/5/26
3 Months Ago
6/6/25 to 6/6/26
1 Year Ago
9/4/24 to 9/4/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
Hold
9 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
3 Hold rating(s)
Sell
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$107.43$118.33$133.92$202.43
Forecasted Upside42.71% Upside58.55% Upside68.46% Upside32.19% Upside
Consensus RatingHoldHoldHoldModerate Buy

ZTS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZTS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zoetis Stock vs. The Competition

TypeZoetisHealthcare CompaniesBroader Market
Consensus Rating Score
2.32
2.30
2.53
Consensus RatingHoldHoldModerate Buy
Predicted Upside40.72% Upside871.78% Upside13.65% Upside
News Sentiment Rating
Positive News

See Recent ZTS News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/25/2026
TD Cowen logo
TD Cowen
3 of 5 stars
Steve Scala
Steve Scala
Not Rated
Lower TargetBuy$104.00 ➝ $94.00+21.87%
8/25/2026
Cantor Fitzgerald logo
Cantor Fitzgerald
5 of 5 stars
 Set Target$94.00+21.87%
8/20/2026
Stifel Nicolaus logo
Stifel Nicolaus
4 of 5 stars
Jonathan Block
Jonathan Block
4 of 5 stars
Lower TargetHold$85.00 ➝ $80.00+4.19%
8/11/2026Lower TargetBuy$112.00 ➝ $96.00+27.60%
8/11/2026Lower TargetOutperform$146.00 ➝ $110.00+46.54%
8/10/2026 DowngradeHoldStrong Sell
8/10/2026Lower TargetNeutral$90.00 ➝ $80.00+7.42%
8/7/2026Set Target$85.00+14.19%
8/7/2026Lower TargetNeutral$85.00 ➝ $80.00+10.30%
8/7/2026Lower TargetOverweight$130.00 ➝ $115.00+58.36%
8/6/2026Reiterated RatingOutperformMarket Perform
7/6/2026Lower TargetBuy$140.00 ➝ $95.00+26.18%
7/1/2026Lower TargetEqual Weight$136.00 ➝ $85.00+18.25%
6/12/2026 DowngradeSell (D+)Sell (D)
5/27/2026Reiterated RatingBuyHold
3/10/2026 Reiterated RatingMarket Perform
2/26/2026Reiterated RatingBuy$160.00+23.89%
2/13/2026Boost TargetNeutral$135.00 ➝ $140.00+11.48%
12/15/2025 UpgradeBuy
11/20/2025Initiated CoverageSector Weight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:16 AM ET.


Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 2, 2026. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

Zoetis
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Zoetis Inc.:

  • Zoetis Inc. currently trades at $76.22, which is significantly below the consensus price target of $109.615, suggesting substantial upside potential for investors who believe the market has overreacted to recent negative news.
  • The company offers a dividend yield of 2.74%, providing a steady income stream for investors, which is particularly attractive given the stock's recent decline and the company's established position in the animal health sector.
  • Zoetis Inc. reported earnings per share of $1.87 in the most recent quarter, beating the consensus estimate of $1.85, indicating that the company is still capable of delivering strong profitability despite revenue challenges.
  • Institutional investors such as Van ECK Associates Corp and Moore Capital Management LP have recently increased their stakes in Zoetis Inc., signaling confidence in the company's long-term value and stability.
  • The company has a beta of 0.73, which is lower than the market average, suggesting that Zoetis Inc. may offer a more stable investment with less volatility compared to broader market movements.

Zoetis
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Zoetis Inc. for these reasons:

  • Zoetis Inc. has experienced a significant decline in stock price, hitting a 52-week low of $71.00, which reflects a substantial drop from its 52-week high of $155.15, indicating strong downward pressure on the stock.
  • The company's revenue for the most recent quarter was $2.47 billion, which fell short of the consensus estimate of $2.50 billion, and revenue was down 0.2% year-over-year, suggesting challenges in maintaining growth.
  • Zoetis Inc. has lowered its full-year 2026 earnings per share guidance to $6.150-$6.250, which is below the consensus estimate of $6.870, indicating that the company expects weaker performance than analysts had anticipated.
  • Short interest in Zoetis Inc. has increased, with 16,781,231 shares shorted as of the most recent record date, representing 4.07% of the float, which suggests that a significant portion of investors are betting against the stock.
  • The consensus rating for Zoetis Inc. is "Hold," with an average price target of $109.615, but the stock is trading well below this level, indicating that analysts are cautious about the company's near-term prospects.

ZTS Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Zoetis is $107.43, with a high forecast of $190.00 and a low forecast of $80.00.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZTS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZTS, but not buy additional shares or sell existing shares.

According to analysts, Zoetis's stock has a predicted upside of 42.71% based on their 12-month stock forecasts.

Over the previous 90 days, Zoetis's stock had 2 downgrades by analysts.

Analysts like Zoetis more than other "healthcare" companies. The consensus rating score for Zoetis is 2.32 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how ZTS compares to other companies.


MarketBeat monitors more than a dozen sources for Zoetis analyst ratings, with the most recent rating issued on 8/25/2026.
From Our Partners